JHPCY (JHPCY)
Healthcare · PNK
Price as at 1 Oct 2026, 01:24 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
JHPCY trades at $12.00, close to the $10.24 our fair value estimate puts on the business. On this measure the market and the model broadly agree, so the interesting question is which of them is wrong.
Our moat model scores it 82 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 37.8 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
JHPCY dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.058 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
About JHPCY
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
JHPCY passes 3 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
JHPCY peers
The largest companies in the same industry (Drug Manufacturers - Specialty & Generic), then in the same sector.
- TKPHF Takeda Pharmaceutical Company Limited
- GALDY Galderma Group AG
- HLNCF Haleon plc
- TEVA Teva Pharmaceutical Industries Limited
- UTHR United Therapeutics Corporation
- VTRS Viatris Inc.
- NBIX Neurocrine Biosciences, Inc.
- ELAN Elanco Animal Health Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is JHPCY (JHPCY) undervalued?
Against our fair value estimate of $10.24, JHPCY at $12.00 is 15% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is JHPCY's P/E ratio?
JHPCY trades at 37.8 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does JHPCY (JHPCY) pay a dividend?
Yes. JHPCY yields 0.43% at the current share price. It has paid $0.058 per share over the trailing twelve months. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its JHPCY data?
Fundamentals for JHPCY come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:24 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for JHPCY, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.